Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Innoviva, Inc.INVA · Entity 4679 | See Remarks | May 20, 2024 | May 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Innoviva, Inc.
Report date May 20, 2024 · Filed May 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,510 |
Reported balance
After 2024-05-20 transaction · row 1
1 source rowRow 1 · 2024-05-20 · Tax withholding · Disposed 268 · Balance 40,510 F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Entasis Therapeutics Holdings Inc.
Report date July 07, 2022 · Filed July 11, 2022
Section 16 reporting ended · disclosed 2022-07-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-07 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-07-07 · Other · Disposed 17,572 · Balance 0 F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-07-11 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was cancelled and converted into the right to receive a right to receive a number of RSUs in respect of shares of Innoviva common stock equal to (x) the number of Shares subject to Issuer RSUs immediately prior to the Effective Time, multiplied by (y) the Offer Price, divided by (z) the per share volume-weighted average price of Innoviva common stock for the 10 business days prior to the closing date of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-11 · Other · Disposed 33,333 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.86 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-11 · Other · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-11 · Other · Disposed 15,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 | Direct | 0 |
Reported balance
After 2022-07-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-07-11 · Other · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price").
F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was cancelled and converted into the right to receive a right to receive a number of RSUs in respect of shares of Innoviva common stock equal to (x) the number of Shares subject to Issuer RSUs immediately prior to the Effective Time, multiplied by (y) the Offer Price, divided by (z) the per share volume-weighted average price of Innoviva common stock for the 10 business days prior to the closing date of the Merger.
F3: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2024 Filed May 22, 2024 00:15 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 268 | $16.13 | $4,322.84 |
DisclosureSEC source: 0000899140-24-000628 · form4.xml · nonDerivative · entry 1 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,510 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 00:02 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 27,338 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001104659-24-032002 · tm248180-2_4seq1.xml · derivative · entry 2 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,438 Underlying: Common Stock · 27,338 shares Expires 2034-03-05 F2 · derivative.exercise_date: 25% of the options will vest on February 20, 2025 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Ronsheim's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Ronsheim experiences a termination of employment by the Innoviva, Inc. without "cause" or by Dr. Ronsheim for "good reason" (each as defined in Dr. Ronsheim's employment agreement) within 24 months following a "change in control," subject to an effective release of claims. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 00:02 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,768 | $14.88 | $189,987.84 |
DisclosureSEC source: 0001104659-24-032002 · tm248180-2_4seq1.xml · nonDerivative · entry 1 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,778 F1 · shares: The Reporting Person was granted a one time-based restricted stock unit ("RSU"). Twenty-five percent of the shares subject to the RSU shall vest on February 20, 2025, 6.25% on May 20, 2025, and an additional 6.25% on the final day of each 3-month period thereafter, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The grant was approved by the Compensation Committee of the Board of Directors of the Company. Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 02:31 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 807 | $15.80 | $12,750.60 |
DisclosureSEC source: 0001104659-24-026716 · tm246891-2_4seq1.xml · nonDerivative · entry 1 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,010 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| January 18, 2024 Filed Jan 23, 2024 02:16 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNonqualified Stock Option · Derivative | 60,000 | $0.00 Strike: $16.05 | $0.00 |
DisclosureSEC source: 0000899140-24-000058 · form4.xml · derivative · entry 2 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,100 Underlying: Common Stock · 60,000 shares Expires 2034-01-17 F2 · derivative.exercise_date: 25% of the options will vest on February 20, 2025 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Ronsheim's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Ronsheim experiences a termination of employment by the Innoviva, Inc. without "cause" or by Dr. Ronsheim for "good reason" (each as defined in Dr. Ronsheim's employment agreement) within 24 months following a "change in control," subject to an effective release of claims. Read SEC document |
| January 18, 2024 Filed Jan 23, 2024 02:16 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 1,600 | $16.05 | $25,680.00 |
DisclosureSEC source: 0000899140-24-000058 · form4.xml · nonDerivative · entry 1 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,817 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 16:09 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001104659-22-078801 · tm2220760-9_4seq1.xml · derivative · entry 6 Ronsheim Matthew · CIK 0001824386 · Chief of Pharma Sciences & MFG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 16:09 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-22-078801 · tm2220760-9_4seq1.xml · derivative · entry 5 Ronsheim Matthew · CIK 0001824386 · Chief of Pharma Sciences & MFG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 16:09 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001104659-22-078801 · tm2220760-9_4seq1.xml · derivative · entry 4 Ronsheim Matthew · CIK 0001824386 · Chief of Pharma Sciences & MFG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 16:09 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherStock Option (right to buy) · Derivative | 33,333 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001104659-22-078801 · tm2220760-9_4seq1.xml · derivative · entry 3 Ronsheim Matthew · CIK 0001824386 · Chief of Pharma Sciences & MFG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price. Read SEC document |
| July 11, 2022 Filed Jul 11, 2022 16:09 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-078801 · tm2220760-9_4seq1.xml · nonDerivative · entry 2 Ronsheim Matthew · CIK 0001824386 · Chief of Pharma Sciences & MFG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was cancelled and converted into the right to receive a right to receive a number of RSUs in respect of shares of Innoviva common stock equal to (x) the number of Shares subject to Issuer RSUs immediately prior to the Effective Time, multiplied by (y) the Offer Price, divided by (z) the per share volume-weighted average price of Innoviva common stock for the 10 business days prior to the closing date of the Merger. F2 · price: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was cancelled and converted into the right to receive a right to receive a number of RSUs in respect of shares of Innoviva common stock equal to (x) the number of Shares subject to Issuer RSUs immediately prior to the Effective Time, multiplied by (y) the Offer Price, divided by (z) the per share volume-weighted average price of Innoviva common stock for the 10 business days prior to the closing date of the Merger. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:09 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | OtherCommon Stock | 17,572 | $2.20 | $38,658.40 |
DisclosureSEC source: 0001104659-22-078801 · tm2220760-9_4seq1.xml · nonDerivative · entry 1 Ronsheim Matthew · CIK 0001824386 · Chief of Pharma Sciences & MFG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). F1 · price: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price"). Read SEC document |
| January 18, 2022 Filed Jan 19, 2022 16:04 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005425 · tm223320-10_4seq1.xml · nonDerivative · entry 1 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,572 F1 · shares: This award vests over four years with twenty-five percent of the award vesting on each anniversary of the date of grant, subject to the reporting person's continued employment with the Company. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 16:05 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Tax withholdingCommon Stock | 3,669 | $2.94 | $10,786.86 |
DisclosureSEC source: 0001104659-21-133635 · tm2131811-3_4seq1.xml · nonDerivative · entry 1 Ronsheim Matthew · CIK 0001824386 · Chief, Pharma Sciences & MFG. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,572 F1 · shares: Represents shares withheld solely for purposes of the payment of taxes arising in connection with the vesting of restricted stock units on November 2, 2021. The number of shares withheld was determined based on the closing price on the last trading day prior to vesting, which was November 1, 2021. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 16:05 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | SaleCommon Stock | 3,759 | $3.19 | $11,991.21 |
DisclosureSEC source: 0001104659-21-128054 · tm2130633-1_4.xml · nonDerivative · entry 2 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,241 F2 · shares: Represents shares sold solely for purposes of the payment of taxes arising in connection with the vesting of restricted stock units on October 19, 2021. The number of shares sold was determined based on the closing price on the last trading day prior to vesting, which was October 18, 2021. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 16:05 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-128054 · tm2130633-1_4.xml · nonDerivative · entry 1 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Acquired as a result of the satisfaction of the performance criteria of the underlying award as of the date stated. Fifty percent of this award vested on such date and the remaining fifty percent will vest on the first anniversary of such date, subject to the reporting person's continued employment with the Company. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 16:04 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantEmployee Stock Option (Right to Buy) · Derivative | 33,333 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001104659-22-023783 · tm226724-9_4seq1.xml · derivative · entry 2 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires 2031-07-15 F2 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 40,000 shares of issuer's common stock granted to the Reporting Person on September 17, 2019. In exchange, the Reporting Person received a replacement option for 33,333 shares of issuer's common stock, having an exercise price of $2.44 per share. F3 · derivative.exercise_date: Sixty-nine percent (69%) of this award will vest on July 16, 2022, and one-fifteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date. Read SEC document |
| July 16, 2021 Filed Feb 15, 2022 16:04 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $5.12 | Not disclosed |
DisclosureSEC source: 0001104659-22-023783 · tm226724-9_4seq1.xml · derivative · entry 1 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2029-09-16 F2 · price: On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 40,000 shares of issuer's common stock granted to the Reporting Person on September 17, 2019. In exchange, the Reporting Person received a replacement option for 33,333 shares of issuer's common stock, having an exercise price of $2.44 per share. F1 · derivative.exercise_date: The option provided for vesting as follows: Twenty-five percent (25%) of the option award will vest on September 17, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 16:09 UTC | Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-005318 · tm213545-5_4seq1.xml · nonDerivative · entry 1 Ronsheim Matthew · CIK 0001824386 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.